Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Categories
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Integrating Pharmacology and A Root Cause Medicine Approach to Cardiovascular Care

Medically reviewed by 
 
Integrating Pharmacology and A Root Cause Medicine Approach to Cardiovascular Care

Cardiovascular disease (CVD) is the leading cause of death among American adults, with a person dying every 33 seconds. For the over 127 million adults living in the US with CVD, despite advancements in prescription medications, CVD management remains an ongoing challenge.

Root Cause medicine can provide a more patient-centric approach to enhance care by addressing the underlying causes of CVD. This article explores the concept of integrating pharmacological treatments with root-cause medicine principles to manage CVD.

[signup]

What is Cardiovascular Diseases (CVD)?

Cardiovascular disease (CVD) is a category of conditions that affect the heart and blood vessels. Common types of CVD include coronary artery disease, hypertension, and heart failure. These conditions are often multifactorial, with a number of risk factors such as a person's genetics, lifestyle, and environmental factors playing significant roles in their development.

Coronary Artery Disease 

Coronary artery disease (CAD) occurs when the blood vessels that supply blood to the heart become narrowed or blocked. The most common causes are due to the buildup of cholesterol plaques (atherosclerosis) in the arteries and excess inflammation. This can lead to chest pain (angina), heart attacks, and other long-term issues.

Hypertension

Hypertension, or high blood pressure, is a risk factor for CVD. Defined as 130/80 mm Hg, hypertension occurs when the force of blood against the arterial walls of the arteries is consistently higher than it should be. Over time, called resistant hypertension, this condition can damage the arteries and lead to heart disease, stroke, and other health problems.

Heart Failure

Heart failure occurs when the heart is unable to pump enough blood to meet the body's needs. It can result from conditions such as CAD, hypertension, and diabetes, and can lead to persistent symptoms such as fatigue, shortness of breath, and swelling in the legs.

The Role of Pharmacology in Cardiovascular Care 

Pharmacology, also referred to by pharmacists as pharmacotherapy, is the cornerstone of traditional CVD management, providing symptomatic relief and reducing the risk of serious complications. Common pharmacological agents used in CVD management include a number of prescription drug classes including statins, beta-blockers, ACE inhibitors, ARBs, and anticoagulants.

Statins 

As the drug class with one of the highest total annual prescriptions in the US in 2021, statins are administered to lower cholesterol levels–like low-density lipoprotein (LDL) cholesterol–which plays an instrumental role in the development of atherosclerosis. By inhibiting the enzyme HMG-CoA reductase, statins reduce the production of cholesterol, leading to a lower LDL. This process can help prevent the formation of atherosclerotic plaques and reduce the risk of cardiovascular events.

Beta-blockers 

Commonly used to manage hypertension and other heart-related conditions, beta blockers work by blocking the effects of adrenaline on the beta-adrenergic receptors in the heart, which can reduce the heart rate and blood pressure. Beta-blockers also help improve heart function and can be beneficial for patients with heart failure or a history of heart attacks.

Angiotensin-converting enzyme (ACE) inhibitors 

ACE inhibitors are a class of medications used to manage hypertension and heart failure. They work by inhibiting the conversion of angiotensin I to angiotensin II, a powerful vasoconstrictor. This leads to vasodilation, which helps lower blood pressure, reduce the workload on the heart, and improve cardiac outcomes.

Angiotensin II receptor blockers (ARBs)

ARBs are an often forgotten but important drug class used in cardiovascular care due to their ability to block the effects of angiotensin II, a hormone that causes blood vessels to constrict. By dilating blood vessels and reducing blood pressure, ARBs can help manage conditions in a treatment protocol for hypertension, heart failure, and post-heart attack care.

Anticoagulants

Anticoagulants, such as warfarin and direct oral anticoagulants (DOACs), are used to prevent blood clots in patients with certain types of CVD, such as atrial fibrillation or venous thromboembolism. These medications inhibit the clotting process, reducing the risk of stroke or other thrombotic events.

Traditional pharmacology in the treatment of CVD focuses on symptom management and risk factor reduction but may overlook underlying causes. Medications such as those described in this section are prescribed to control cholesterol levels, blood pressure, and heart function. While these medications can be effective in controlling symptoms and reducing the chance of adverse events, they often do not address the causes of CVD. Functional medicine practitioners use a whole-person approach to cardiovascular care beyond symptom management, combining pharmacology with root cause medicine principles to optimize patient outcomes.

Principles of Root Cause Medicine in Cardiovascular Care

Functional medicine practitioners recognize the importance of addressing the root causes for more comprehensive care. Root cause medicine, within the context of cardiovascular care, is an approach that identifies the contributors to the development, progression, and complications of CVD. Rather than only focusing on symptoms, this type of precision medicine views the presenting condition as a result of a combination of factors rather than a single cause. 

Functional medicine prioritizes the value of personalized care, as the etiology of CVD can vary greatly from person to person. These factors can include genetic predispositions, such as a family history, as well as lifestyle modifications, such as diet, supplements, movement, sleep quality, and stress management. Treatment plans are tailored to each person, taking into account their health goals.

Integrating Pharmacology with Root Cause Approaches

Integrating pharmacological treatments with functional medicine is fundamental for enhancing CVD management. This integrative approach addresses lifestyle modifications, dietary changes, and physical activity to combat both the symptoms and the underlying causes of CVD, leading to improved patient outcomes. 

Physical Activity

Encouraging patients to engage in regular movement can improve cardiovascular health and reduce the risk of CVD. Exercise programs tailored to individual needs and abilities can complement pharmacological treatments by improving heart function, normalizing blood pressure, and reducing cholesterol levels.

Sleep

At night, the body repairs and restores itself, including the heart and blood vessels. Adequate sleep helps regulate blood pressure, reduce inflammation, and maintain healthy blood sugar levels–all of which are important for cardiovascular health. Insufficient sleep has been linked to an increased risk of developing hypertension, coronary artery disease, and stroke. Ongoing research demonstrating an adequate amount of sleep each night in combination with pharmacotherapy may be key for maintaining a healthy heart.

Nutrition 

Dietary interventions, such as the Mediterranean diet or the Dietary Approaches to Stop Hypertension or DASH diet, can help reduce the risk of CVD and improve outcomes in patients with existing CVD. These diets emphasize whole grains, fruits, vegetables, lean proteins, and healthy fats while limiting processed foods and refined sugar.

Patients who followed a Mediterranean diet have shown a lower risk of developing CVD compared to those who did not. One clinical trial showed that when losartan (ARB) was taken in combination with the DASH diet, there was a greater blood pressure-lowering effect than on its own.

Personalized medicine plays a crucial role in tailoring treatment plans for patients diagnosed with CVD. By taking into account individual differences, personalized medicine allows functional medicine practitioners to prescribe drugs in tandem with complementary lifestyle modifications that are most likely to be effective for each patient.

Challenges and Considerations 

When integrating traditional pharmacotherapy with root cause approaches in CVD management, there are many moving parts to consider. Patient compliance with lifestyle modifications can be a significant barrier, as patients may find it challenging to maintain new healthy habits. There may also be cost implications associated with implementing lifestyle interventions, such as nutrient-dense fruits and vegetables, and group exercise programs.

Supportive interdisciplinary teams, inclusive of functional medicine practitioners, will play a vital role in the shift to a comprehensive patient-centered treatment paradigm. Through a collaborative approach, healthcare teams can work together with the patient to educate them on their multifaceted treatment plan. Monitoring patient progress and adjusting regimens as needed will be essential to effectively manage CVD using an integrative approach.

The Future of Cardiovascular Care 

The future of cardiovascular care is poised to undergo a transformation, driven by the growing need for precision medicine. This shift represents a departure from the one-size-fits-all approach to cardiovascular care, towards a more patient-centered model that considers risk factors differences and treatment goals. Innovations in technology and research are in part driving this integration, with personalized medicine playing a role in tailoring treatment plans to individual patients.

New technologies, such as diagnostic imaging tools, wearable devices, health-focused apps, telemedicine, and specialized biomarker tests, are also enabling patients to take a more empowered role in preventing and managing their health outcomes. The integration of root cause medicine, traditional pharmacotherapy, and technology is poised to advance integrated cardiovascular care. 

[signup]

Key Takeaways

Integrating pharmacology with a root cause medicine approach offers a more patient-centered strategy for improving cardiovascular outcomes.

By optimizing diet, exercise, sleep, and stress management for CVD patients, functional medicine practitioners can amplify the effectiveness of prescription medications, to enhance quality of life.

Further research and cross-functional collaboration across healthcare providers are needed to explore new pharmacological treatments, lifestyle interventions, and technologies to improve cardiovascular care for future generations.

The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No items found.
  1. Mayo Clinic. (2022). Heart disease. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-disease/symptoms-causes/syc-20353118 
  2. CDC. (2023). Heart disease facts. Centers for Disease Control and Prevention. https://www.cdc.gov/heartdisease/facts.htm 
  3. American Heart Association. (2023). Heart disease and stroke statistics - 2023 update. Professional.heart.org. https://professional.heart.org/en/science-news/heart-disease-and-stroke-statistics-2023-update 
  4. Yoshimura, H. (2023). Using Functional Medicine As Personalized Medicine. Rupa Health. https://www.rupahealth.com/post/using-functional-medicine-as-personalized-medicine 
  5. Sing, C. F., Stengård, J. H., & Kardia, S. L. (2003). Genes, environment, and cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology, 23(7), 1190–1196. https://doi.org/10.1161/01.ATV.0000075081.51227.86
  6. Mayo Clinic. (2022). Coronary Artery Disease . Mayo Clinic; Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/symptoms-causes/syc-20350613 
  7. Cloyd, J. (2023). Inflammation and Heart Disease: A Functional Medicine Approach to Prevention and Treatment. Rupa Health. https://www.rupahealth.com/post/inflammation-and-heart-disease-a-functional-medicine-approach-to-prevention-and-treatment 
  8. Mayo Clinic. (2024). High Blood Pressure (Hypertension) . Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/symptoms-causes/syc-20373410 
  9. Cloyd, J. (2023). A Functional Medicine Hypertension Protocol. Rupa Health. https://www.rupahealth.com/post/functional-medicine-hypertension-protocol 
  10. Yoshimura, H. (2024). Strategies for Managing Resistant Hypertension. Rupa Health. https://www.rupahealth.com/post/strategies-for-managing-resistant-hypertension 
  11. Cloyd, J. (2023). A Functional Medicine Post Stroke Protocol: Testing, Therapeutic Diet, and Integrative Therapy Options. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-post-stroke-protocol-testing-supplements-and-integrative-therapy-options 
  12. Mayo Clinic. (2023). Heart Failure. Mayo Clinic; Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-failure/symptoms-causes/syc-20373142 
  13. Pharmacotherapy - an overview | ScienceDirect Topics. (2018). Www.sciencedirect.com. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/pharmacotherapy 
  14. Kane, S. P. (2019). The Top 300 of 2021. Clincalc.com. https://clincalc.com/DrugStats/Top300Drugs.aspx 
  15. Cleveland Clinic. (2022). Statins: Types, Uses and Side Effects. Cleveland Clinic. https://my.clevelandclinic.org/health/treatments/22282-statins
  16. Cloyd, K. (2023). How to interpret your lipid panel results. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-your-lipid-panel-results 
  17. Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016). A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. Journal of clinical lipidology, 10(3), 472–489. https://doi.org/10.1016/j.jacl.2015.11.010 
  18. Mayo Clinic. (2023). What you should know about beta blockers. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/beta-blockers/art-20044522# 
  19. Safi, S., Sethi, N. J., Korang, S. K., Nielsen, E. E., Feinberg, J., Gluud, C., & Jakobsen, J. C. (2021). Beta-blockers in patients without heart failure after myocardial infarction. The Cochrane database of systematic reviews, 11(11), CD012565. https://doi.org/10.1002/14651858.CD012565.pub2
  20. Mayo Clinic. (2023). What do ACE inhibitors do for heart health? Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/ace-inhibitors/art-20047480# 
  21. Bertrand M. E. (2004). Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Current medical research and opinion, 20(10), 1559–1569. https://doi.org/10.1185/030079904X4185 
  22. Cleveland Clinic. (2022). Angiotensin II Receptor Blockers (ARBs): Uses and Side Effects. Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/23327-angiotensin-ii-receptor-blockers 
  23. Al Khalaf, M. M., Thalib, L., & Doi, S. A. (2009). Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis. American journal of cardiovascular drugs : drugs, devices, and other interventions, 9(1), 29–43. https://doi.org/10.1007/BF03256593 
  24. Mayo Clinic. (2024). Warfarin (Oral Route) Description and Brand Names - Mayo Clinic. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/warfarin-oral-route/description/drg-20070945 
  25. Julia, S., & James, U. (2017). Direct Oral Anticoagulants: A Quick Guide. European cardiology, 12(1), 40–45. https://doi.org/10.15420/ecr.2017:11:2 
  26. Grimaldi-Bensouda, L., Le Heuzey, J. Y., Ferrières, J., Leys, D., Davy, J. M., Martinez, M., Dialla, O., Smadja, D., Nighoghossian, N., Benichou, J., Nordon, C., Touzé, E., & Abenhaim, L. (2021). Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors. Stroke, 52(10), 3121–3131. https://doi.org/10.1161/STROKEAHA.120.032704 
  27. Bryant, A. (2024). How to Lower Blood Cholesterol Levels: Natural and Pharmacologic Options. Rupa Health. https://www.rupahealth.com/post/how-to-lower-blood-cholesterol-levels-natural-and-pharmacologic-options 
  28. Neibling, K. (2023). Complementary and Integrative Medicine Treatments for Hypertension and Cardiovascular Disease. Rupa Health. https://www.rupahealth.com/post/complementary-and-integrative-medicine-treatments-for-hypertension-and-cardiovascular-disease 
  29. Cloyd, J. (2023). The Role Of Nutrition And Dietary Supplements In Preventing And Managing Cardiovascular Disease. Rupa Health. https://www.rupahealth.com/post/the-role-of-nutrition-and-dietary-supplements-in-preventing-and-managing-cardiovascular-disease
  30. Weinberg, J. (2022). What is the Mediterranean Diet?. Rupa Health. https://www.rupahealth.com/post/4-science-backed-health-benefits-of-the-mediterranean-diet 
  31. Cloyd, J. (2022). 9 Health Benefits of the DASH Diet. Rupa Health. https://www.rupahealth.com/post/9-health-benefits-of-the-dash-diet 
  32. Martínez-González, M. A., Gea, A., & Ruiz-Canela, M. (2019). The Mediterranean Diet and Cardiovascular Health. Circulation Research, 124(5), 779–798. https://doi.org/10.1161/circresaha.118.313348
  33. Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., 3rd, Simons-Morton, D. G., Karanja, N., Lin, P. H., & DASH-Sodium Collaborative Research Group (2001). Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. The New England journal of medicine, 344(1), 3–10. https://doi.org/10.1056/NEJM200101043440101
  34. Cloyd, J. (2023). The Role of Physical Activity in Promoting Heart Health. Rupa Health. https://www.rupahealth.com/post/the-role-of-physical-activity-and-exercise-in-promoting-heart-health-including-the-use-of-alternative-exercise-modalities-such-as-tai-chi-and-qigong 
  35. Khakham, C. (2023). Integrative Cardiology: Lifestyle and Natural Approaches to Heart Health. Rupa Health. https://www.rupahealth.com/post/integrative-cardiology-lifestyle-and-natural-approaches-to-heart-health 
  36. Yoshimura, H. (2023). The Remarkable Power of Exercise on Our Health: A Comprehensive Overview. Rupa Health. https://www.rupahealth.com/post/the-remarkable-power-of-exercise-on-our-health-a-comprehensive-overview 
  37. Tian, D., & Meng, J. (2019). Exercise for Prevention and Relief of Cardiovascular Disease: Prognoses, Mechanisms, and Approaches. Oxidative medicine and cellular longevity, 2019, 3756750. https://doi.org/10.1155/2019/3756750 
  38. Varady, K. A., & Jones, P. J. H. (2005). Combination Diet and Exercise Interventions for the Treatment of Dyslipidemia: an Effective Preliminary Strategy to Lower Cholesterol Levels? The Journal of Nutrition, 135(8), 1829–1835. https://doi.org/10.1093/jn/135.8.1829 
  39. Weinberg, J. (2023). The Science of Sleep: Functional Medicine for Restorative Sleep. Rupa Health. https://www.rupahealth.com/post/the-science-of-sleep-functional-medicine-for-restorative-sleep 
  40. Nagai, M., Hoshide, S., & Kario, K. (2010). Sleep duration as a risk factor for cardiovascular disease- a review of the recent literature. Current cardiology reviews, 6(1), 54–61. https://doi.org/10.2174/157340310790231635 
  41. Hall, M. H., Brindle, R. C., & Buysse, D. J. (2018). Sleep and cardiovascular disease: Emerging opportunities for psychology. The American psychologist, 73(8), 994–1006. https://doi.org/10.1037/amp0000362
  42. DeCesaris, L. (2024). Maximizing Patient Engagement: Innovative Strategies for Functional Medicine Practices. Rupa Health. https://www.rupahealth.com/post/maximizing-patient-engagement-innovative-strategies-for-functional-medicine-practices 
  43. Yoshimura, H. (2024). Exploring Collaborative Opportunities Between Functional Medicine and Conventional Medical Practitioners. Rupa Health. https://www.rupahealth.com/post/exploring-collaborative-opportunities-between-functional-medicine-and-conventional-medical-practitioners 
  44. Yoshimura, H. (2023). Why More Medical Professionals are Turning Towards Functional Medicine. Rupa Health. https://www.rupahealth.com/post/why-more-medical-professionals-are-turning-towards-functional-medicine 
  45. DeCesaris, L. (2024b). Wearable Devices: A New Frontier in Chronic Disease Management for Healthcare Practitioners. Rupa Health. https://www.rupahealth.com/post/wearable-devices-a-new-frontier-in-chronic-disease-management-for-healthcare-practitioners 
  46. DePorto, T. (2022). Worried About Heart Disease? Ask Your Provider for These 6 Specialty Labs at Your Next Appointment. Rupa Health. https://www.rupahealth.com/post/worried-about-heart-disease-ask-your-provider-for-these-6-specialty-labs-at-your-next-appointment 
  47. Greenan, S. (2021). What is Functional Medicine? How Do I Find A Functional Medicine Practitioner? Rupa Health. https://www.rupahealth.com/post/what-is-functional-medicine
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.